In addition to ALK gene rearrangement, ALK gene copy number gain (CNG) and amplification have also been reported in NSCLC [11], colorectal carcinoma [12], renal cell carcinoma (RCC) [13], rhabdomyosarcoma [14], and neuroblastoma tumor [15], but their biological significance and relation to ALK inhibitor susceptibility remain uncertain. This evidence concerns the gene ALK and renal cell carcinoma.